A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Exclusion Criteria

• •Pregnant or breastfeeding, or intention of becoming pregnant within the timeframe in which contraception is required
• •Participants who have confirmed or suspected Progressive Multifocal Leukoencephalopathy (PML)
• •Known or suspected history of Hemophagocytic Lymphohistiocytosis/ Macrophage Activation Syndrome (HLH/MAS) or neurotoxicity with prior therapies
• •Known presence of other neurologic disorders that may mimic MS
• •History of currently active primary or secondary (non-drug-related) immunodeficiency
• •Significant or uncontrolled medical disease which would preclude patient participation
• •High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV Ig, or acute blood product transfusions
• •History of recurrent serious infections or chronic infection
• •Prior treatment with CAR T-cell therapy, gene-therapy product, total body irradiation, bone marrow transplantation, allograft organ transplant, or hematopoietic stem cell transplant at any point
• •Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period.
• •Inability to complete an MRI scan